Navigation Links
Accuri Cytometers Completes $13 Million Series C Financing

--New Funds will Support Expanded Commercialization of the Revolutionary

Accuri C6 Flow Cytometer(R) System--

ANN ARBOR, Mich., July 8 /PRNewswire/ -- Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. Current investors including Baird Venture Partners and Arboretum Ventures also participated in the financing. Accuri will use the proceeds from the Series C financing primarily to expand its commercialization activities for the Accuri C6 Flow Cytometer(R) System. Bahaa Fam, Venture Partner, Fidelity Biosciences and Harry Wilcox, Partner, Flagship Ventures, will join the company's Board of Directors.

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's flow cytometer system is a full featured bench-top cell analysis system that provides capabilities similar to industry-leading flow cytometers in a more user-friendly format and at a fraction of the cost.

"This successful Series C financing led by Fidelity Biosciences and Flagship Ventures reflects the progress we have achieved in developing and commercializing our breakthrough flow cytometer system," said Jennifer Baird, CEO of Accuri. "Our strong initial acceptance in the marketplace is now ramping up and these new resources will enable us to further expand the reach of our marketing and sales efforts. We are pleased that our existing venture investors all participated in this round, and we look forward to the contributions of our new Board members."

Accuri created its revolutionary C6 system with input from hundreds of researchers who use flow cytometry, including many whose research has been fettered by resource constraints in their facilities. The company teamed with Menlo Innovations, which brought its unique, award-winning methods to the development of the Accuri system's easy-to-use analysis software, a critical component of the approach. Accuri's innovations, coupled with its state of the art components, result in a cytometer that is powerful, robust, compact and affordable, at less than one-third the cost of the market leader.

"We are enthusiastic about our investment in Accuri," said Bahaa Fam, Venture Partner, Fidelity Biosciences. "By making flow cytometry technology more affordable, accessible and usable, Accuri's high performance systems have the potential to accelerate and broaden the scope of biomedical research. We welcome this opportunity to help the company progress to the next level."

"Flow cytometry is an essential tool in biomedical research, and Accuri's outstanding team has responded to the need for accessible, affordable easy-to- use systems by completely re-inventing the flow cytometer from the ground up," said Harry Wilcox, Partner at Flagship Ventures. "The Accuri Flow Cytometer System is already gaining traction among researchers, and we are very optimistic about the future potential of this promising company."

"As Accuri continues to commercialize its revolutionary technology, we are very pleased to welcome Fidelity and Flagship representatives as new investors and as Board members," said Pete Shagory, Accuri Chairman and a Partner at Baird Venture Partners. "Their expertise in the research tools space will be especially valuable as Accuri expands its efforts to effectively grow the business."

About Accuri Cytometers

Accuri Cytometers, Inc. is an Ann Arbor-based life sciences company developing and marketing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer(R) is a full featured bench-top cell and bead analysis system that provides similar capabilities to those of industry-leading flow cytometers in an easy-to-use format and at a fraction of their cost. The Accuri system was engineered from the start to be compact, powerful and user-friendly, while also being affordable by most research laboratories. For more information, visit

About Fidelity Biosciences

Fidelity Biosciences is a division of Devonshire Investors, which invests private equity on behalf of Fidelity Investments. For more than 30 years, the firm has had a significant presence in the venture capital and private equity industry. This provides Fidelity Biosciences with the flexibility, and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value. For more information, please visit

About Flagship Ventures

Flagship Ventures is a venture capital firm focused on creating, financing and building innovative companies. Founded in 2000, Flagship manages over $600 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: Adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, Morphotek, PerSeptive Biosystems and TripAdvisor. For more information please visit

About Baird Venture Partners

Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early- and expansion-stage business services and healthcare/life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. With a global team of 80 professionals in nine offices across the United States, Europe and Asia, Baird Private Equity and its affiliates have raised and managed approximately $2.4 billion in capital and invested in over 220 companies since the 1980s. For more information, please visit and

About Arboretum Ventures

Arboretum Ventures is an early-stage venture capital firm specializing in the healthcare sector. Arboretum Ventures focuses primarily on investments in medical technology and healthcare services. Arboretum invests throughout the United States, with a special interest in the Midwest region. Founded in 2002 with headquarters in Ann Arbor, Mich., Arboretum Ventures currently manages $85 million in capital. For more information, please visit

For additional information, contact:

Accuri Cytometers Media

Jennifer A. Baird GendeLLindheim BioCom Partners

Chief Executive Officer Barbara Lindheim

(734) 994-8000 (212) 918-4650

SOURCE Accuri Cytometers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
3. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
4. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
5. Boston Scientific Completes Acquisition of CryoCor
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
8. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
9. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
10. China-Biotics, Inc. Completes Foundation for Its New Plant
11. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Post Your Comments:
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, ... agreement to develop and commercialize intellectual property rights belonging to The University of ... 2009, and affords exclusive worldwide rights to intellectual property based on use of ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
Breaking Biology Technology:
... Green Mountain Energy Company to take the necessary steps in ... enabling them to operate as a "carbon neutral" analytical laboratory. ... ... Alkemists Pharmaceuticals today announced that it has partnered with Green Mountain ...
... 30 , - Shares Acquired From Biggar ... biotechnology company,focused on eye disease, vascular disease and ... based in Belgium have together acquired an 8%,stake ... Biggar Limited, a,charitable foundation that is ThromboGenics largest ...
... SAN DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... second quarter 2008,financial results after the NASDAQ Global ... afternoon, Jack Lief, Arena,s President and Chief,Executive Officer, ... Chief Financial Officer, will host a conference call ...
Cached Biology Technology:
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):
... began a rapid period of change called the Cambrian ... life forms over many millions of years that ultimately ... help palaeontologists chronicle the evolution of life since then, ... billion years that preceded the Cambrian Period is challenging, ...
... turnover and remodelling of lipid membranes could help phytoplankton cope ... team led by Patrick Martin of the National Oceanography Centre ... rapidly change the chemical composition of its cell membranes in ... the process may be important for nutrient cycling and the ...
... University researchers focusing on rice genetics are providing a ... nutrients. Their research provides insight into ways of ... research. Frank White, professor of plant pathology, and ... in partnership with researchers at three other institutions, of ...
Cached Biology News:
MAb to Myoglobin Cardiac...
... ALH 4000 workstation is the simplest, easiest-to-use ... introduce automated liquid handling capabilities,into their labs, ... to support routine applications on a separate ... walk-away automation even when you have ...
... Covance has generated hybridomas against a ... project initiation, you are provided with ... Hybridoma cell lines developed by Covance ... A typical hybridoma development project has ...
... normalization is essential for hunting and ... approaches, such as EST sequencing projects, ... methods are not well suited for ... Evrogen TRIMMER kit, though, is specially ...
Biology Products: